MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rpth.2024.102474

Медицинская библиотека · Research and practice in thrombosis and haemostasis · 2024

Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders.

van Hoorn Evelien S, Willems Sterre P E, Al Arashi Wala, de Moor Annick S, van Kwawegen Calvin B, Teela Lorynn, Oude Voshaar Martijn A H, Kremer Hovinga Idske C L, Schutgens Roger E G, Schols Saskia E M, Leebeek Frank W G, Haverman Lotte, Cnossen Marjon H, Gouw Samantha C, Lingsma Hester F, SYMPHONY consortium and the Dutch research group for PROMIS implementation in inherited bleeding disorders

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Patient-reported outcomes measurement information system (PROMIS) measures can be used to measure patient-reported outcomes. PROMIS measures, including computer adaptive tests (CATs) and short forms, have demonstrated the ability to adequately assess outcomes in patients with hemophilia. It is, however, unclear if PROMIS measures are suitable for patients with von Willebrand disease (VWD), inherited platelet function disorders (IPFDs), and rare bleeding disorders (RBDs).

OBJECTIVES

To evaluate the feasibility, measurement properties, and relevance of PROMIS measures in adults with VWD, IPFDs, and RBDs.

METHODS

In this cross-sectional multicenter study, adults with VWD, IPFDs, and RBDs completed 9 PROMIS measures and the Short Form-36 version 2 (SF-36v2) electronically. Feasibility was determined by the number of completed items and floor/ceiling effects. Measurement properties included construct validity based on a multitrait-multimethod analysis and reliability using the reliability coefficient and greatest lower bound. Relevance was evaluated based on comparison with the Dutch general population.

RESULTS

In total, 111 patients (median age, 57 years [IQR, 44-67]; 60% VWD, 16% IPFD, 24% RBD) participated. Mean number of items answered varied from 5.3 to 8.7 (range, 4-12) per PROMIS CAT in patients with VWD. Construct validity was supported for all CATs and all instruments had a good reliability (≥0.70). The PROMIS measures had less ceiling effects than the SF-36v2.

CONCLUSION

The PROMIS measures are a feasible, valid, and reliable alternative for the SF-36v2 in patients with primarily nonsevere forms of VWD. The relevance of the selected measures was limited. Additional research is necessary to evaluate the PROMIS measures in adults with IPFDs and RBDs.

Для цитирования: van Hoorn Evelien S, Willems Sterre P E, Al Arashi Wala, de Moor Annick S, van Kwawegen Calvin B, Teela Lorynn, Oude Voshaar Martijn A H, Kremer Hovinga Idske C L, Schutgens Roger E G, Schols Saskia E M, Leebeek Frank W G, Haverman Lotte, Cnossen Marjon H, Gouw Samantha C, Lingsma Hester F, SYMPHONY consortium and the Dutch research group for PROMIS implementation in inherited bleeding disorders. Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders.. Research and practice in thrombosis and haemostasis. 2024. DOI: 10.1016/j.rpth.2024.102474.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.